Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial.
Rial-Crestelo M, Lubusky M, Parra-Cordero M, Krofta L, Kajdy A, Zohav E, Ferriols-Perez E, Cruz-Martinez R, Kacerovsky M, Scazzocchio E, Roubalova L, Socias P, Hašlík L, Modzelewski J, Ashwal E, Castellá-Cesari J, Cruz-Lemini M, Gratacos E, Figueras F; RATIO37 Study Group.
Rial-Crestelo M, et al. Among authors: ashwal e.
Lancet. 2024 Feb 10;403(10426):545-553. doi: 10.1016/S0140-6736(23)02228-6. Epub 2024 Jan 11.
Lancet. 2024.
PMID: 38219773
Clinical Trial.